-
1 Comment
Avinger, Inc is currently in a long term uptrend where the price is trading 14.0% above its 200 day moving average.
From a valuation standpoint, the stock is 99.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 8.6.
Avinger, Inc's total revenue rose by 6.6% to $3M since the same quarter in the previous year.
Its net income has increased by 9.6% to $-5M since the same quarter in the previous year.
Finally, its free cash flow grew by 12.5% to $-3M since the same quarter in the previous year.
Based on the above factors, Avinger, Inc gets an overall score of 5/5.
Exchange | NASDAQ |
---|---|
CurrencyCode | USD |
ISIN | US0537348858 |
Sector | Healthcare |
Industry | Medical Instruments & Supplies |
Market Cap | 2M |
---|---|
PE Ratio | None |
Target Price | 5 |
Beta | 1.09 |
Dividend Yield | None |
Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. Its lumivascular products comprise Lightbox imaging consoles; the Ocelot and Tigereye family of devices, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. The company is also developing IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. The company was incorporated in 2007 and is based in Redwood City, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for AVGR using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025